FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108685959> ?p ?o ?g. }

• W2108685959 endingPage "e320" @default.
• W2108685959 startingPage "e314" @default.
• W2108685959 abstract "In this study we examined the effectiveness of atomoxetine for the treatment of oppositional defiant disorder comorbid with attention-deficit/hyperactivity disorder.Patients were aged 6 to 12 years and met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnostic criteria for attention-deficit/hyperactivity disorder with a Swanson, Nolan, and Pelham Rating Scale-Revised attention-deficit/hyperactivity disorder subscale score above age and gender norms; Clinical Global Impressions-Severity Scale score of > or = 4; and Swanson, Nolan, and Pelham Rating Scale-Revised oppositional defiant disorder subscale score of > or = 15. Patients were randomly assigned in a 2:1 ratio to receive 1.2 mg/kg per day of atomoxetine (n = 156) or placebo (n = 70) for 8 weeks. Treatment effect on oppositional defiant disorder and attention-deficit/hyperactivity disorder symptoms was measured by using the investigator-rated Swanson, Nolan, and Pelham Rating Scale-Revised.Repeated-measures analysis demonstrated a statistically significant difference favoring atomoxetine over placebo in the reduction of Swanson, Nolan, and Pelham Rating Scale-Revised oppositional defiant disorder total scores. There were significant pairwise treatment differences at weeks 2 and 5 but not at week 8 postbaseline. A last-observation-carried-forward analysis showed Swanson, Nolan, and Pelham Rating Scale-Revised scores at endpoint for the atomoxetine and placebo groups were significantly different for attention-deficit/hyperactivity disorder symptoms but not for oppositional defiant disorder symptoms. Atomoxetine was superior to placebo in a last-observation-carried-forward analysis of Clinical Global Impression-Improvement and Clinical Global Impression-Severity scores.This study confirms previous findings that patients with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder show statistically and clinically significant improvement in attention-deficit/hyperactivity disorder symptoms and global clinical functioning when treated with atomoxetine. It remains uncertain, however, whether atomoxetine exerts a specific and enduring effect on oppositional defiant disorder symptoms." @default.
• W2108685959 created "2016-06-24" @default.
• W2108685959 creator A5000058346 @default.
• W2108685959 creator A5010821842 @default.
• W2108685959 creator A5026562442 @default.
• W2108685959 creator A5032347235 @default.
• W2108685959 creator A5056726531 @default.
• W2108685959 creator A5062183573 @default.
• W2108685959 creator A5065649213 @default.
• W2108685959 creator A5089114657 @default.
• W2108685959 creator A5091487905 @default.
• W2108685959 date "2008-02-01" @default.
• W2108685959 modified "2023-10-14" @default.
• W2108685959 title "Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder" @default.
• W2108685959 cites W1967288147 @default.
• W2108685959 cites W1976881402 @default.
• W2108685959 cites W2004124985 @default.
• W2108685959 cites W2004825421 @default.
• W2108685959 cites W2018408113 @default.
• W2108685959 cites W2021930047 @default.
• W2108685959 cites W2031042693 @default.
• W2108685959 cites W2032874175 @default.
• W2108685959 cites W2046160508 @default.
• W2108685959 cites W2061120182 @default.
• W2108685959 cites W2096323169 @default.
• W2108685959 cites W2099365033 @default.
• W2108685959 cites W2103758243 @default.
• W2108685959 cites W2103793045 @default.
• W2108685959 cites W2117095140 @default.
• W2108685959 cites W2133610675 @default.
• W2108685959 cites W2141551611 @default.
• W2108685959 cites W2162557073 @default.
• W2108685959 cites W4237214904 @default.
• W2108685959 cites W4249508602 @default.
• W2108685959 cites W4254230094 @default.
• W2108685959 doi "https://doi.org/10.1542/peds.2006-1880" @default.
• W2108685959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18245404" @default.
• W2108685959 hasPublicationYear "2008" @default.
• W2108685959 type Work @default.
• W2108685959 sameAs 2108685959 @default.
• W2108685959 citedByCount "75" @default.
• W2108685959 countsByYear W21086859592012 @default.
• W2108685959 countsByYear W21086859592013 @default.
• W2108685959 countsByYear W21086859592014 @default.
• W2108685959 countsByYear W21086859592015 @default.
• W2108685959 countsByYear W21086859592016 @default.
• W2108685959 countsByYear W21086859592017 @default.
• W2108685959 countsByYear W21086859592021 @default.
• W2108685959 countsByYear W21086859592022 @default.
• W2108685959 countsByYear W21086859592023 @default.
• W2108685959 crossrefType "journal-article" @default.
• W2108685959 hasAuthorship W2108685959A5000058346 @default.
• W2108685959 hasAuthorship W2108685959A5010821842 @default.
• W2108685959 hasAuthorship W2108685959A5026562442 @default.
• W2108685959 hasAuthorship W2108685959A5032347235 @default.
• W2108685959 hasAuthorship W2108685959A5056726531 @default.
• W2108685959 hasAuthorship W2108685959A5062183573 @default.
• W2108685959 hasAuthorship W2108685959A5065649213 @default.
• W2108685959 hasAuthorship W2108685959A5089114657 @default.
• W2108685959 hasAuthorship W2108685959A5091487905 @default.
• W2108685959 hasConcept C118552586 @default.
• W2108685959 hasConcept C138496976 @default.
• W2108685959 hasConcept C142724271 @default.
• W2108685959 hasConcept C15744967 @default.
• W2108685959 hasConcept C204787440 @default.
• W2108685959 hasConcept C27081682 @default.
• W2108685959 hasConcept C2776000289 @default.
• W2108685959 hasConcept C2777112843 @default.
• W2108685959 hasConcept C2778781522 @default.
• W2108685959 hasConcept C2780783007 @default.
• W2108685959 hasConcept C2909253567 @default.
• W2108685959 hasConcept C70410870 @default.
• W2108685959 hasConcept C71924100 @default.
• W2108685959 hasConcept C83849319 @default.
• W2108685959 hasConceptScore W2108685959C118552586 @default.
• W2108685959 hasConceptScore W2108685959C138496976 @default.
• W2108685959 hasConceptScore W2108685959C142724271 @default.
• W2108685959 hasConceptScore W2108685959C15744967 @default.
• W2108685959 hasConceptScore W2108685959C204787440 @default.
• W2108685959 hasConceptScore W2108685959C27081682 @default.
• W2108685959 hasConceptScore W2108685959C2776000289 @default.
• W2108685959 hasConceptScore W2108685959C2777112843 @default.
• W2108685959 hasConceptScore W2108685959C2778781522 @default.
• W2108685959 hasConceptScore W2108685959C2780783007 @default.
• W2108685959 hasConceptScore W2108685959C2909253567 @default.
• W2108685959 hasConceptScore W2108685959C70410870 @default.
• W2108685959 hasConceptScore W2108685959C71924100 @default.
• W2108685959 hasConceptScore W2108685959C83849319 @default.
• W2108685959 hasIssue "2" @default.
• W2108685959 hasLocation W21086859591 @default.
• W2108685959 hasLocation W21086859592 @default.
• W2108685959 hasOpenAccess W2108685959 @default.
• W2108685959 hasPrimaryLocation W21086859591 @default.
• W2108685959 hasRelatedWork W1968417351 @default.
• W2108685959 hasRelatedWork W1969779240 @default.
• W2108685959 hasRelatedWork W2315859520 @default.
• W2108685959 hasRelatedWork W2316132077 @default.
• W2108685959 hasRelatedWork W2566238729 @default.

• next